Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

Caers, J. (Jo); Paiva, B. (Bruno); Zamagni, E. (Elena); Leleu, X. (Xavier); Bladé, J. (Joan); Kristinsson, S.Y. (S. Y.); Touzeau, C. (C.); Abildgaard, N. (N.); Terpos, E. (Evangelos); Heusschen, R. (R.); Ocio, E.M. (Enrique M.); Delforge, M. (M.); Sezer, O. (O.); Beksac, M. (Meral); Ludwig, H. (Heinz); Merlini, G. (G.); Moreau, P. (Philippe); Zweegman, S. (Sonja); Engelhardt, M. (Monika); Rosiñol, L. (Laura)

Keywords:

Solitary plasmacytoma
Extramedullary plasmacytoma
Myeloma
Plasma cell dyscrasia
PET/CT
MRI
Radiotherapy

Issue Date:

2018

Publisher:

BioMed Central

Project:

1114242 - - Circulating tumor DNA to monitor treatment response and resistance in mantle cell lymphoma

ISSN:

1756-8722

Note:

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Citation:

Caers, J. (Jo); Paiva, B. (Bruno); Zamagni, E. (Elena); et al. "Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel". Journal of hematology and oncology. 11 (10), 2018,

Abstract

Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow aspiration can detect a low monoclonal plasma cell infiltration which indicates a high risk of early progression to an overt myeloma disease. Before treatment initiation, whole body positron emission tomography–computed tomography or magnetic resonance imaging should be performed to exclude the presence of additional malignant lesions. For decades, treatment has been based on high-dose radiation, but studies exploring the potential benefit of systemic therapies for high-risk patients are urgently needed. In this review, a panel of expert European hematologists updates the recommendations on the diagnosis and management of patients with solitary plasmacytoma.

URI:

https://hdl.handle.net/10171/65654

DOI:

10.1186/s13045-017-0549-1

Appears in Collections:

DA - CIMA - Hemato-oncología - Mieloma - Artículos de Revista

Files in This Item: